Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With <scp>NSCLC</scp> Treated With <scp>PD</scp>–1/<scp>PD</scp>‐<scp>L1</scp> Inhibitors
Our study shows delta-He as a promising prognostic biomarker for lung cancer patients treated with PD-1/PD-L1 inhibitors, highlighting its potential to guide therapeutic decisions and improve patient management in a non-invasive manner. Further research is necessary to validate delta-He's predictive and prognostic value across broader populations and in combination with other biomarkers, emphasizing its role in advancing personalized oncology.
Authors
- Green Hong (ORCID: https://orcid.org/0009-0006-9841-2514)
- Chaeuk Chung (ORCID: https://orcid.org/0000-0002-3978-0484)
- Da Hyun Kang (ORCID: https://orcid.org/0000-0002-3495-0931)
- Hee Sun Park (ORCID: https://orcid.org/0000-0002-9730-8524)
- Jeong Eun Lee (ORCID: https://orcid.org/0000-0001-6173-2748)
- Song‐I Lee
Institutions
- Chungnam National University Hospital (KR)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/cam4.70826
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Research Foundation
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea